Clinical Trials Logo

Clinical Trial Summary

Systemic sclerosis (SSc) is an uncommon chronic rheumatic disease with an unknown cause and unpredictable course. The inability, in addition to easy fatigability, starts a vicious circle that leads to a fast deterioration of physical conditions that cause a reduction of aerobic exercise capacity and, consequently, of health-related quality of life (HRQoL). Aerobic exercise has already been shown to be safe and effective in improving exercise capacity and HRQoL of patients with chronic cardiovascular and pulmonary diseases. However, few studies have evaluated the role of specific exercise programs on the muscular impairment in SSc. Nevertheless, the results obtained in preliminary reports are promising, and, for these reasons, the management of muscular impairment in SSc could include an appropriate rehabilitation program besides pharmaceutical and surgical treatments.

The primary aim of this study will be to evaluate the effect of an individualized exercise program performed at home on aerobic capacity evaluated by 6 minutes walking test.

Secondary aims will be to evaluate: 1- VO2max, measured by cardiopulmonary test; 2- the effect of the same program on the muscular strength of upper and lower limbs; 3- the efficacy of a self-administered stretching program for finger joint motion. Secondary aims will be also 1-to ascertain whether a comprehensive exercise program may affect, besides physical function, HRQoL; 2- and to evaluate the adherence during two periods of three months, one whit and one without supervision and reinforcement by a phone call.

All the patients with a diagnosis of SSc, according to the criteria of American College of Rheumatology (ACR), who attended the Rheumatologic outpatient clinic of our institution will be evaluated in order to participate in the rehabilitation program. The pneumological examination and two days of screening and testing will take place at the outpatient's clinic of Respiratory Medicine and Sport of our institution.


Clinical Trial Description

This will be a randomized, controlled, six months parallel group study. The flow chart of the study is reported in table 1. Participants initially will undergo 2 days of screening and testing. During the first visit patients will sign an informed consent, will undergo clinical assessment, pulmonary function testing, measurement of anthropometric data and body composition by bioimpedentiometry. They will perform a graded exercise test on a cycloergometer and will complete questionnaires to assess HRQoL (short form-36, SF-36) and functional abilities (health assessment questionnaire disability index, HAQ-DI). During the second visit, the participants will carry out the hand mobility in scleroderma test (HAMIS), six minutes walking test (6MWT), will undergo measurements of quadriceps and biceps strength, and handgrip test. After completion of testing and screening, patients who will meet the selection criteria will be randomly assigned to one of two groups 1) home-care rehabilitation group (HCRG); 2) control group (CG). The first group will begin a six months program of exercise training. The patients of the second group will be given generic recommendations to increase physical activity.

The patients in the first group, during a session in our outpatient clinic, will be instructed by a physiotherapist how to perform the physical exercise program at home. In particular, they will learn how to use the stationary bike and how to perform the exercises for upper limbs. Furthermore, the patient of the first group will be instructed how to fill in a card in which they will record the exercises performed daily. Throughout the first three months of the training period, the patients received a phone call from a physiotherapist once monthly, during which the adherence to exercise program will be reinforced. Particularly, it will be asked about the adherence to and the acceptance of exercise program, and the presence of side effects. Also, the control group will receive a phone call with the same schedule, but only in order to evaluate health status and to give a general recommendation about the positive effect of the aerobic exercise. From the third to the sixth month, both groups will not receive a monthly call, in order to evaluate the adherence to the program in the absence of supervision.

After 3 and 6 months, the subjects will undergo a complete 2 days of testing, using the same schedule described for a baseline.

The exercise program consists of aerobic exercise on a stationary bike, muscular endurance training of the upper limb and stretching exercises for finger joint motion. The exercise on the stationary bike and muscular endurance training will be performed on alternate days, three times a week.

A stationary cycle (Energetics ct220p, Neomark Sarl, Luxembourg) will be given to each patient for lower limb training. Each session will consist of three phases. In the first one, the patient will pedal for 5 minutes without inserting the brake. In the second phase, the patient will be instructed to set the brake at a load equal to 60% of the watts achieved at the peak of the maximal ergocycle exercise test. This phase consists in two periods of fifteen minutes divided by recovery interval of three minutes. It will be followed by five minutes of cool-down without load. The frequency of pedalling will be about 60 rotation/min during the second phase and less than 50 during the other phases.

For upper limbs training the patients will perform ten repetitions for three times that consists in lifting and lowering repeatedly a weight from the waist to the shoulders, alternating periods of exercise and three minutes of rest. The load will be calculated as the 60% of predicted 1-RM. Warm up and stretching of upper limbs, shoulders and neck will be performed before and after each exercise session respectively.

For the first two weeks, for both types of exercises of the program, the load will be reduced by 20%.

For finger stretching to the patients will be given written and illustrated instructions on self-administered exercises, and will be directed to perform it every day, both in the morning and in the evening.

During the rehabilitation period, the patients will report each day on a diary for each type of exercise whether the tasks were complete, partially or not executed which corresponds a score of 1, 0.5, 0 respectively.

The attendance rate at the training session will be calculated by the ratio between the amount of the score obtained from the diary and the scheduled sessions multiplied for 100. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03614208
Study type Interventional
Source Universita di Verona
Contact
Status Completed
Phase N/A
Start date February 1, 2017
Completion date March 1, 2018

See also
  Status Clinical Trial Phase
Completed NCT03274076 - Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc) Phase 1/Phase 2
Completed NCT04300426 - Safety and Efficacy of Anaerobic Cultivated Human Intestinal Microbiome Transplantation in Systemic Sclerosis (ReSScue) Phase 2
Recruiting NCT06058091 - RY_SW01 Cell Injection Therapy in Systemic Sclerosis Phase 1/Phase 2
Recruiting NCT04356755 - Subcutaneous Injections of ASC to Heal Digital Ulcers in Patients With Scleroderma. Phase 2
Suspended NCT06210945 - Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis Phase 2
Not yet recruiting NCT05947682 - Manufacturing of Allogeneic Adipose Tissue-derived Mesenchymal Stromal Cells for Treatment of Severe Systemic Sclerosis N/A
Not yet recruiting NCT05177380 - Efficacy of a Personalized Rehabilitation Program of Facial Involvement in Systemic Sclerosis N/A
Not yet recruiting NCT04303208 - Sirtuin 3 and Sirtuin 7 in Systemic Sclerosis N/A
Recruiting NCT02551042 - CSL Behring Sclero XIII Phase 2
Terminated NCT02246348 - Evaluating Lung Doppler Signals in Patients With Systemic Sclerosis (SSc) N/A
Terminated NCT02243111 - Detecting Pulmonary Arterial Hypertension (PAH) in Patients With Systemic Sclerosis (SSc) by Ultrasound N/A
Completed NCT01933334 - Safety and Tolerability of Pirfenidone in Patients With Systemic Sclerosis−Related Interstitial Lung Disease (SSc-ILD) (LOTUSS) Phase 2
Completed NCT01468792 - Hemodynamic Changes in Connective Tissue Disease N/A
Terminated NCT00848107 - Open-Label Study of Oral Treprostinil in Digital Ulcers Phase 2
Completed NCT00984932 - Effect of Rosuvastatin on Systemic Sclerosis-related Pulmonary Hypertension Phase 3
Completed NCT00074568 - Scleroderma Registry
Not yet recruiting NCT06412614 - Evaluation of Patients With Systemic Sclerosis Without Specific or Associated Autoantibodies
Terminated NCT00622687 - Effect of Different Iloprost Doses on Symptoms in Systemic Sclerosis Phase 2
Recruiting NCT04464434 - Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis Phase 4
Recruiting NCT04246528 - SPIN Self-Management Feasibility Trial With Progression to Full-scale Trial (SPIN-SELF) N/A